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Abstract
Obejctives: Regardless of diabetes status, hyperglycemia on arrival 
for  patients  presenting  with  acute  coronary  syndrome,  has  been 
associated with adverse outcomes including death. The aim of this 
study is to look at the frequency and prognostic significance of acute 
phase hyperglycemia among patients attending the coronary care unit 
with acute coronary syndrome over the in-hospital admission days.
Methods: The study included 287 consecutive patients in the Al-
Faiha Hospital in Basrah (Southern Iraq) during a one year period 
from December 2007 to November 2008. Patients were divided 
into two groups with respect to admission plasma glucose level 
regardless of their diabetes status (those with admission plasma 
glucose of <140 mg/dl (7.8 mmol/L) and those equal to or more 
than that). Acute phase hyperglycemia was defined as a non-fasting 
glucose level equal to or above 140 mg/dl (7.8 mmol/L) regardless 
of past history of diabetes.
Results:  Sixty  one  point  seven  percent  (177)  of  patients  were 
admitted with plasma glucose of ≥140 mg/dl (7.8 mmol/L). There 
were  no  differences  were  found  between  both  groups  regarding 
the mean age, qualification, and smoking status, but males were 
predominant  in  both  groups. A  family  history  of  diabetes,  and 
hypertension, were more frequent in patients with plasma glucose of 
≥140 mg/dl (7.8 mmol/L). There were no differences between the 
two groups regarding past history of ischemic heart disease, stroke, 
lipid profile, troponin-I levels or type of acute coronary syndrome. 
Again  heart  failure  was  more  common  in  the  admission  acute 
phase hyperglycemia group, but there was no difference regarding 
arrhythmia, stroke, or death. Using logistic regression with heart 
failure as the dependent variable we found that only the admission 
acute phase hyperglycemia (OR=2.1344, 95% CI=1.0282-4.4307; 
p=0.0419) was independently associated with heart failure. While 
male gender, family history of diabetes mellitus, hypertension and 
diabetes  were  not  independently  associated  with  heart  failure.
Conclusion:  Admission acute phase hyperglycemia of ≥140 mg/dl 
(7.8 mmol/L) was associated with heart failure in this study.
Keywords: Acute coronary syndrome; Diabetes; Plasma glucose; 
Stress hyperglycemia.
Introduction
Regardless  of  diabetes  status,  hyperglycemia  on  arrival  for 
patients  presenting  with  acute  coronary  syndrome  (ACS)  has 
been  associated  with  adverse  outcomes,  including  death.1-5 Both 
acute phase hyperglycemia (Stress hyperglycemia) and diabetes are 
associated with adverse outcomes in acute myocardial infarction 
(MI), with higher reported incidences of congestive heart failure, 
cardiogenic shock, and death.6-13
Elevation of glucose could be due to pre-existing, but not yet 
detected type 2 diabetes, impaired glucose tolerance, or it can be 
a marker of existing insulin resistance and/or beta-cell failure that 
through different mechanisms other than diabetes contributed to 
worse outcome after myocardial infarction.14 Acute hyperglycemia 
is independently associated with impaired left ventricular function; 
it abolishes ischemic pre-conditioning, generating oxidative stress, 
it worsens endothelial function, increases platelet activation, and 
amplifies  inflammatory  immune  reactions  after  acute  coronary 
syndrome  and  subsequent  mortality.14  Furthermore,  it  exerts  a 
profound  negative  impact  on  the  development  of  the  coronary 
collateral circulation in vivo.15
Patients  with  higher  baseline  blood  glucose  levels  in  the 
absence of diabetes and after adjustment for co-variants are at a 
significantly greater risk of developing coronary artery disease and 
heart  failure.14,16,17 Some  found  hyperglycemia-associated  risk  is 
greater in patients with acute myocardial infarction who do not have 
antecedent diabetes than in those with diabetes.3,12 Others showed 
that this risk is similar across patient groups.18,19
The aim of this study is to look at the frequency and prognostic 
significance of acute phase hyperglycemia among patients attending 
the coronary care unit with ACS over the in-hospital admission 
days.
Methods
This  was  a  cross-sectional  hospital  based  study  of  all  patients 
who presented to the hospital with ACS. The study included 287 
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consecutive patients with ACS admitted to the CCU in the Al-Faiha 
Hospital in Basrah (Southern Iraq) during a one year period from 
December 2007 to November 2008. The patients were followed for 
major events and complications, only in hospital until discharge.
Patients  with  final  discharge  diagnosis  of  ACS,  including 
unstable angina (UA) and MI, ST segment elevation myocardial 
infarction (STEMI) or non-ST segment ST elevation myocardial 
infarction (NSTEMI) or new LBBB were included in this study. The 
European Society of Cardiology/American College of Cardiology 
definition of myocardial infarction was adopted, which includes any 
of the following criteria that satisfy diagnosis of an acute, evolving or 
recent myocardial infarction: typical rise and gradual fall (troponin) 
or more rapid rise and fall (creatine kinase-MB) of biochemical 
markers of myocardial necrosis, with at least one of the following:
a)  Ischemic symptoms
b)  Development of pathological Q-waves on electrocardiogram
c)  Electrocardiogram changes indicative of myocardial ischemia 
(ST-segment elevation or depression).20
Criteria for STEMI were any two of the following; a) cardiac 
chest pain lasting at least 30 minutes, b) > 0.1 mV ST elevation in 
at least one standard lead, c) > 0.2 mV ST elevation in two or more 
contiguous chest leads, or d) new LBBB and biochemical markers of 
myocardial injury.21 Unstable angina was defined by at least one of 
the following: worsening of previous stable pattern of angina, chest 
pain at rest or minimal effort with transient ST-segment elevation 
or  depression  on  ECG,  or  elevation  of  biochemical  markers  of 
myocardial injury not reaching the criteria for MI (Cardiac troponin 
I (cTnI) [0.1 - 1.49 ng/ml]).22,23
Baseline clinical characteristics including demographic, clinical, 
and biochemical data were collected on admission. A ‘smoker’ was 
defined as a patient smoking any cigarette in the past 3 months. 
Family history of diabetes was considered positive if the first degree 
relatives were diabetics. Previous history of ischemic heart disease 
(IHD) was considered positive if there was any history of admission 
to CCU with records by doctor suggestive of IHD. Standing height 
and weight measurements were completed with subjects wearing 
light weight clothing and no shoes. Height was measured to the 
nearest centimeter and weight was measured to the nearest 0.5 kg. 
Body mass index (BMI) was calculated as body weight in kilograms 
divided by the squared value of body height in meters (kg/m2).
Blood  pressure  was  measured  with  a  mercury 
sphygmomanometer on the right arm. Hypertension was defined as 
systolic blood pressure ≥140 mmHg and/or diastolic blood pressure 
≥90  mmHg  and/or  current  medication  with  antihypertensive 
drugs. The admission plasma glucose concentrations from blood 
samples drawn on arrival in the emergency room were recorded.
Acute phase hyperglycemia was defined as a non-fasting glucose 
level equal or above 140 mg/dl (7.8 mmol/L) regardless of past 
history  of  diabetes.24,25  Newly  detected  diabetes  was  defined  as 
hyperglycemia (fasting ≥126 mg/dl [7 mmol/l]), or postprandial 
≥200mg/dl (11.1 mmol/l), which required therapy on discharge. 
Diabetes was recorded in patients on insulin, oral hypoglycemic 
drugs, or dietary restriction before admission.
Within 1 hour of admission, a blood sample was taken from the 
patients for biochemical analysis. Plasma glucose was assessed by 
the enzymatic method (glucose oxidase). Lipid concentrations were 
determined by using enzymatic methods. Low density lipoprotein 
(LDL)  cholesterol  was  calculated  according  to  the  Friedewald 
formula.26  Cardiac  troponin  I  was  measured  using  VIDAS 
Troponin I by enzyme linked fluorescent assay on admission. Serum 
cTnI values were sorted and identified as normal ([<0.1 ng/ml] or 
<0.01 µg/l), intermediate (0.1 to 1.49 ng/ml), or elevated (≥1.5 ng/
ml).27 Patients were classified into 3 groups based on their history of 
diabetes and their plasma glucose levels on admission:
Group 1 (n=104 [36.2% ] ): Non-diabetic patients without acute 
phase hyperglycemia.
Group 2 (n=78 [27.2% ] ): Non-diabetic patients with acute phase 
hyperglycemia.
Group 3 (n=105 [36.6%] ): Diabetic patients.
Complications reported in the CCU were arrhythmia, heart 
failure, stroke and death. The diagnosis of heart failure required 
there to be symptoms of breathlessness, accompanied by physical 
findings of basal crepitations or a third heart sound and requiring 
treatment  with  diuretics  and  echocardiographic  finding  of 
systolic heart failure. Arrhythmia was considered for any rhythm 
disturbance that required therapy.
Data are expressed as mean ± standard deviation values for 
continuous variables and as percentages for categorical variables. 
Comparisons were made by one-way analysis of variance (ANOVA) 
and Student t test for continuous variables. The Chi-square analysis 
or Fisher’s exact test was used to compare categorical variables.
To  determine  the  Independent  effects  of  admission  acute 
phase hyperglycemia on complications, variables were entered into 
the logistic regression model. A p value of <0.05 was considered 
statistically significant. All statistical analysis were performed using 
the SPSS 15.0 software package.
Results
Patient  characteristics  are  presented  in  Table  1.  There  was  no 
difference between all three study groups regarding the mean age, 
qualifications,  marital,  or  smoking  state.  Males  predominated 
in the three study groups. A family history of diabetes was more 
significantly higher among the diabetic group.
There were no differences between study groups regarding past 
history of IHD or stroke, but hypertension was more common 
among the diabetic group and was observed in approximately half 
of the cases. The weight, BMI, and admission hyperglycemia were 
higher in both diabetic and acute phase hyperglycemia groups in 
comparison with the normoglycemia group. No differences were 
found between groups regarding lipoprotein profile, serum cTnI 
levels or final diagnosis of ACS type. Heart failure was the only most 
common finding in the diabetic group while other complications 
such as arrhythmia, stroke, and death were not different among the 
groups.
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Table 1: Study Characteristics in Patients with Normoglycemia, Acute Phase Hyperglycemia, and Diabetes (n=287).
Characteristics Normoglycemia
n=104 (36.2) 
Admission acute phase 
hyperglycemia 
n=78 (27.2) 
Diabetes
n=105 (36.6)
p value
Age  Mean ±SD 63.8 ± 14.6 61.0 ± 12.0 60.5 ± 10.9 0.13
≤60 41 (39.4) 33 (42.3)  52 (49.5) 0.321
>60 63 (60.6) 45 (57.7)  53 (50.5)
Gender Male  80 (76.9) 49 (62.8) 65 (61.9)      0.03
Female  24 (23.0) 29 (37.1) 40 (38.0)
Qualification  3.0 ± 4.5  2.6 ± 4.1  3.6 ± 5.0  0.3
Married 90 (86.5) 61 (78.2) 84 (80) 0.2
Smoker 36 (34.6) 25 (32.0) 34 (32.3) 0.58
Family history of diabetes 25 (24.0) 26 (33.3) 67 (63.8) 0.0001
Previous IHD 27 (25.9) 23 (29.4) 38 (36.1) 0.2
Previous stroke 4 (3.8 ) 3 (3.8) 7 (6.6) 0.5
Hypertension  33 (31.7) 33 (42.3) 53 (50.4) 0.02
Weight (kg)  71.5 ± 13.2 75.7 ± 14.4 78.7 ± 13.3 0.002
BMI (kg/m2)  25.6 ± 4.3 27.4 ± 5.7  27.4 ± 4.0 0.01
Admission plasma glucose (mg/dl) 111.6 ± 16.1 191.3 ± 66.7 258.2 ± 91.9 0.0001
Cholesterol(mg/dl) 212.2 ± 45.1 208.9 ± 39.8 203.0 ± 38.8 0.6
TG(mg/dl) 156.6 ± 77.0 163.5 ± 65.36 165.3 ± 55.3 0.83
HDL-C(mg/dl) 45.6 ± 9.2 50.5 ± 24.3 44.5 ± 10.7    0.2
LDL-C(mg/dl) 136.3 ± 45.4 132.5 ± 38.5  127.1 ± 34.2 0.5
Cardiac troponin I (cTnI)  (ng/ml) 3.5 ± 6.5 5.8 ± 7.6  4.9 ± 6.3 0.2
Final diagnosis STEMI 52 (50.0) 46 (59.0)  59 (56.2) 0.454
NSEMI 18 (17.3)  8 (10.3) 19 (18.1)
UA  34 (32.7)  24 (30.8)  27 (25.7)
Complications
Arrhythmia  9 (8.6) 10 (12.8) 14 (13.3) 0.5
Heart failure 12 (11.5) 14 (17.9) 35 (33.3) 0.0001
Stroke  1 (0.9) 1 (1.2) 5 (4.7) 0.1
Death  4 (3.8) 2 (2.5) 8 (7.6) 0.2
p value for x2  test for dichotomous variables and one way analysis of variance (ANOVA) was used for continuous variables. 
(Figures in parentheses are percentages).
In Table 2, patients are divided into two groups with respect to admission plasma glucose level regardless of the diabetes state. Sixty one 
point seven percent (177) of patients were admitted with plasma glucose of ≥140 mg/dl (7.8 mmol/L). No differences were found between 
both groups regarding mean age, qualifications, smoking status, but males predominated in both groups. Family history of diabetes, and 
hypertension, were more in those with plasma glucose of ≥140 mg/dl (7.8 mmol/L).
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Table 2: Subgroup Characteristics with Respect to Baseline Glucose Determinations.
Characteristics Plasma glucose *<140 
mg/dl (N=110)
Plasma glucose ≥140 mg/
dl (N=177)
p value
Age  Mean ±SD 61.1 ± 11.3 63 ± 14.6  0.23
≤60 47 (42.7) 79 (44.6) 0.807
>60 63 (57.3) 98 (55.4)
Gender Male  85 (77.3) 109 (61.6) 0.006
Female  25 (22.7) 68 (38.4)
Qualification  3.09 ± 4.6 3.2 ± 4.6 0.49
Smoker 56 (31.6) 39 (35.4) 0.29
Family history of diabetes 88 (49.7) 30 (27.2) 0.0002
Previous IHD 55 (31.0) 33 (30) 0.89
Previous stroke 7 (3.9) 7 (6.3) 0.4
Hypertension  82 (46.3) 37 (33.6) 0.03
Weight  77.2 ± 14.1 72.1 ± 13.0 0.003
BMI  27.4 ± 4.9 25.8 ± 4.3 0.007
Cholesterol 206.3 ± 39.1 210.9 ± 45.2 0.57
TG 165.7 ± 59.2 154.3 ± 77.2 0.38
HDL-C 47.5 ± 18.5 45.3 ± 9.3 0.49
LDL-C 129.9 ± 36.3 135.8 ± 45.0  0.45
Cardiac troponin I (cTnI)  (ng/ml) 3.4 ± 6.5 5.4 ± 7.0 0.114
Final diagnosis STEMI  51 (46.4) 106 (59.9) 0.071
NSEMI  19 (7.3) 26 (14.7)
UA  40 (36.4)  45 (25.4)
Complications
Arrhythmia  9 (8.1) 24 (13.5) 0.16
Heart failure 13 (11.8) 48 (27.1) 0.002
Stroke  1 (0.9)  6 (3.4) 0.18
Death  4 (3.6) 10 (5.6) 0.4
* Some of them were diabetics with no admission acute phase hyperglycemia.
p value for x2  test for dichotomous variables, and the Student t test was used for the continuous variables
There were no differences regarding past history of IHD, stroke, lipid profile, troponin-I levels or type of ACS found between both 
groups. Again, heart failure was more common in the admission acute phase hyperglycemia group, but there were no differences in 
arrhythmia, stroke, and death.
In Table 3, using logistic regression with heart failure as the dependent variable, it was noted that only the admission acute phase 
hyperglycemia (OR =2.1344 , 95 % CI = 1.0282-4.4307; p=0.0419) was independently associated with heart failure. While male gender, 
family history of diabetes mellitus, hypertension and diabetes were not independently associated with heart failure.
Table 3: Multivariable Logistic Regression Analysis to see the Independent Association of Heart Failure with Certain Variables.
Variable Odds Ratio 95% Confidence Interval p value
Gender  1.4199 0.7665-2.6304 0.2651
Family history of diabetes 1.1185   0.5990-2.0886 0.7253
Hypertension  1.1930 0.6495-2.1916 0.5694
Diabetes  0.5298 0.2733-1.0270 0.0600
Admission acute phase hyperglycemia 2.1344 1.0282-4.4307 0.0419
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Discussion 
The admission plasma glucose of 140 mg/dl (7.8 mmol/L) and 
above was chosen to select the group of acute phase hyperglycemia. 
In some of the largest observational studies to date, as well as in 
epidemiological analyses of randomized clinical trials, the initial 
mean  24-hour  and  mean  hospitalization  glucose  levels  above 
~120–140 mg/dL (6.7–8.0 mmol/L) appear to be associated with 
the greatest increase in short-term mortality risk, when the entire 
cohort of patients (including those with and without established 
diabetes) is considered.28 It would appear reasonable to consider 
random glucose levels >140 mg/dL (7.8 mmol/L) as the definition 
of hyperglycemia in the acute MI setting.29
In this study, heart failure was the only complication significantly 
associated  with  diabetes.  Arrhythmia,  stroke,  and  death  were 
no more seen among the diabetic or high admission acute phase 
hyperglycemia group. It remains unclear, however, whether glucose 
is behaving as an indicator of the underlying diabetic state or as a 
predisposition or even as a marker of the severity of the ventricular 
injury  and  its  hemodynamic  consequence,  as  opposed  to  a  true 
mediator of unfavorable clinical outcomes.30 
Why was there no increase in hospital mortality in our study? 
Well,  both  short  and  long-term  mortality  increased  in  a  linear 
fashion with higher admission glucose in patients, without known 
diabetes.28 However, among those with established diabetes, only 
patients with severe hyperglycemia (admission glucose >240 mg/
dL [13.2 mmol/L]) experienced a statistically significant increase 
in mortality. 
Properly relying on fasting glycemia may give a better prognostic 
indicator. Suleiman et al. demonstrated that while both admission 
and  fasting  glucose  levels  predicted  30-day  mortality  in  non-
diabetic  patients  with  acute  MI,  fasting  glucose  was  the  better 
discriminator.31
Elevated blood glucose levels in STEMI affect the prognosis of 
patients without diabetes mellitus; however, it is not an independent 
death risk factor of patients with diabetes mellitus, treated with 
percutanous  coronary  intervention.32  Admission  serum  glucose 
concentration was not independently associated with cardiac death 
in a prospective cohort study of 2,127 patients presenting with ACS 
from London hospitals.2
Similar findings were seen by Bellodi et al. among 330 non-
diabetic  patients  with  acute  AMI,  where  cardiogenic  shock, 
infarct site and age, were reported to be the major determinants 
of mortality, while admission plasma glucose failed to reach full 
statistical significance.9
Our  results  suggest  that  high  admission  acute  phase 
hyperglycemia  independently  and  regardless  of  gender,  family 
history  of  diabetes,  and  diabetes  state  or  hypertension,  was 
associated with heart failure. While Foo et al. found that prognostic 
correlates of admission glycemia were unaffected by diabetes status 
and did not differ significantly between patients with acute MI and 
those with unstable angina.2 The mechanisms of the adverse effects 
of acute phase hyperglycemia on ventricular function was not an 
aim of the current study. However, it can be due to adrenergic stress, 
which is itself related to the severity of myocardial injury.33
Conclusion 
This was a single center study with a small sample size. Fasting 
plasma  glucose  and  glycated  hemoglobin  were  not  measured. 
There was also a short-term follow-up period, and the effects of 
hyperglycemia in diabetics were not studied separately. However, 
the fair conclusion based on the findings from this study confirm 
that  admission  acute  phase  hyperglycemia  of  ≥140  mg/dl  (7.8 
mmol/L) was associated with heart failure in this study.
Acknowledgements
The authors wish to thank Lesley Pocock Publisher and Managing 
Director medi+WORLD International World CME for reviewing 
the manuscript.
References 
1.   Norhammar  AM,  Rydén  L,  Malmberg  K.  Admission  plasma  glucose. 
Independent risk factor for long-term prognosis after myocardial infarction even 
in nondiabetic patients. Diabetes Care 1999 Nov;22(11):1827-1831. 
2.  Foo K, Cooper J, Deaner A, Knight C, Suliman A, Ranjadayalan K, et al. A 
single serum glucose measurement predicts adverse outcomes across the whole 
range of acute coronary syndromes. Heart 2003 May;89(5):512-516. 
3.  Wahab NN, Cowden EA, Pearce NJ, Gardner MJ, Merry H, Cox JL; ICONS 
Investigators.  Is  blood  glucose  an  independent  predictor  of  mortality  in 
acute myocardial infarction in the thrombolytic era? J Am Coll Cardiol 2002 
Nov;40(10):1748-1754. 
4.  Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. 
Association of glycaemia with macrovascular and microvascular complications 
of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 
Aug;321(7258):405-412. 
5.   Capes SE, Hunt D, Malmberg K, Gerstein HC. Stress hyperglycaemia and 
increased risk of death after myocardial infarction in patients with and without 
diabetes: a systematic overview. Lancet 2000 Mar;355(9206):773-778. 
6.   Oswald GA, Smith CC, Betteridge DJ, Yudkin JS. Determinants and importance 
of stress hyperglycaemia in non-diabetic patients with myocardial infarction. Br 
Med J (Clin Res Ed) 1986 Oct;293(6552):917-922. 
7.   Lynch M, Gammage MD, Lamb P, Nattrass M, Pentecost BL. Acute myocardial 
infarction  in  diabetic  patients  in  the  thrombolytic  era.  Diabet  Med  1994 
Mar;11(2):162-165. 
8.   Ravid  M,  Berkowicz  M,  Sohar  E.  Hyperglycemia  during  acute  myocardial 
infarction. A six-year follow-up study. JAMA 1975 Aug;233(7):807-809.
9.   Bellodi G, Manicardi V, Malavasi V, Veneri L, Bernini G, Bossini P, et al. 
Hyperglycemia and prognosis of acute myocardial infarction in patients without 
diabetes mellitus. Am J Cardiol 1989 Oct;64(14):885-888. 
10.  Soler NG, Frank S. Value of glycosylated hemoglobin measurements after acute 
myocardial infarction. JAMA 1981 Oct;246(15):1690-1693. 
11.  O’Sullivan JJ, Conroy RM, Robinson K, Hickey N, Mulcahy R. In-hospital 
prognosis of patients with fasting hyperglycemia after first myocardial infarction. 
Diabetes Care 1991 Aug;14(8):758-760. 
12.  Sewdarsen M, Vythilingum S, Jialal I, Becker PJ. Prognostic importance of 
admission  plasma  glucose  in  diabetic  and  non-diabetic  patients  with  acute 
myocardial infarction. Q J Med 1989 May;71(265):461-466. 
13.  Gwilt DJ, Petri M, Lamb P, Nattrass M, Pentecost BL. Effect of intravenous 
insulin  infusion  on  mortality  among  diabetic  patients  after  myocardial 
infarction. Br Heart J 1984 Jun;51(6):626-630. 
14.  Ceriello  A.  Acute  hyperglycaemia:  a  ‘new’  risk  factor  during  myocardial 
infarction. Eur Heart J 2005 Feb;26(4):328-331. 
15.  Weihrauch D, Lohr NL, Mraovic B, Ludwig LM, Chilian WM, Pagel PS, et 
Oman Medical Journal (2011) Vol. 26, No. 2: 85-90Oman Medical Specialty Board
al.  Chronic  hyperglycemia  attenuates  coronary  collateral  development  and 
impairs proliferative properties of myocardial interstitial fluid by production of 
angiostatin. Circulation 2004 May;109(19):2343-2348. 
16.  Nielson C, Lange T. Blood glucose and heart failure in nondiabetic patients. 
Diabetes Care 2005 Mar;28(3):607-611. 
17.  Nielson C, Lange T, Hadjokas N. Blood glucose and coronary artery disease in 
nondiabetic patients. Diabetes Care 2006 May;29(5):998-1001. 
18.  Hadjadj S, Coisne D, Mauco G, Ragot S, Duengler F, Sosner P, et al. Prognostic 
value of admission plasma glucose and HbA in acute myocardial infarction. 
Diabet Med 2004 Apr;21(4):305-310. 
19.  Stranders I, Diamant M, van Gelder RE, Spruijt HJ, Twisk JW, Heine RJ, et 
al. Admission blood glucose level as risk indicator of death after myocardial 
infarction in patients with and without diabetes mellitus. Arch Intern Med 2004 
May;164(9):982-988. 
20.  Myocardial infarction redefined–a consensus document of The Joint European 
Society  of  Cardiology/American  College  of  Cardiology  Committee  for  the 
redefinition of myocardial infarction. Eur Heart J 2000 Sep;21(18):1502-1513. 
21.  Antman EM, Anbe DT, Armstrong PW, Bates ER, Green LA, Hand M, et 
al; American College of Cardiology/American Heart Association Task Force 
on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines 
for the Management of Patients With Acute Myocardial Infarction). ACC/
AHA guidelines for the management of patients with ST-elevation myocardial 
infarction–executive summary: a report of the American College of Cardiology/
American  Heart  Association  Task  Force  on  Practice  Guidelines  (Writing 
Committee to Revise the 1999 Guidelines for the Management of Patients 
With Acute Myocardial Infarction). Circulation 2004 Aug;110(5):588-636. 
22.  Hamm CW, Bertrand M, Braunwald E. Acute coronary syndrome without ST 
elevation: implementation of new guidelines. Lancet 2001 Nov;358(9292):1533-
1538. 
23.  Morrow  DA,  Cannon  CP,  Rifai  N,  Frey  MJ,  Vicari  R,  Lakkis  N,  et  al; 
TACTICS-TIMI 18 Investigators. Ability of minor elevations of troponins I 
and T to predict benefit from an early invasive strategy in patients with unstable 
angina and non-ST elevation myocardial infarction: results from a randomized 
trial. JAMA 2001 Nov;286(19):2405-2412. 
24.  Timmer JR, Bilo HJ, Ottervanger JP, Dambrink JH, Miedema K, Hoorntje JC, 
et al. Dysglycemia in suspected acute coronary syndromes. Eur J Intern Med 
2005 Feb;16(1):29-33. 
25.  Weir CJ, Murray GD, Dyker AG, Lees KR. Is hyperglycaemia an independent 
predictor of poor outcome after acute stroke? Results of a long-term follow up 
study. BMJ 1997 May;314(7090):1303-1306. 
26.  Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of 
low-density lipoprotein cholesterol in plasma, without use of the preparative 
ultracentrifuge. Clin Chem 1972 Jun;18(6):499-502. 
27.  Antman  EM,  Tanasijevic  MJ,  Thompson  B,  Schactman  M,  McCabe  CH, 
Cannon  CP,  et  al.  Cardiac-specific  troponin  I  levels  to  predict  the  risk  of 
mortality  in  patients  with  acute  coronary  syndromes.  N  Engl  J  Med  1996 
Oct;335(18):1342-1349. 
28.  Kosiborod M, Rathore SS, Inzucchi SE, Masoudi FA, Wang Y, Havranek EP, et 
al. Admission glucose and mortality in elderly patients hospitalized with acute 
myocardial infarction: implications for patients with and without recognized 
diabetes. Circulation 2005 Jun;111(23):3078-3086. 
29.  Kosiborod  M.  Blood  glucose  and  its  prognostic  implications  in  patients 
hospitalised  with  acute  myocardial  infarction.  Diab  Vasc  Dis  Res  2008 
Nov;5(4):269-275. 
30.  Inzucchi SE. Hyperglycaemia and its therapy during acute coronary syndromes. 
Diab Vasc Dis Res 2008 Nov;5(4):259. 
31.  Suleiman  M,  Hammerman  H,  Boulos  M,  Kapeliovich  MR,  Suleiman  A, 
Agmon Y, et al. Fasting glucose is an important independent risk factor for 30-
day mortality in patients with acute myocardial infarction: a prospective study. 
Circulation 2005 Feb;111(6):754-760. 
32.  Gasior M, Pres D, Stasik-Pres G, Lech P, Gierlotka M, Hawranek M, et al. Effect 
of blood glucose levels on prognosis in acute myocardial infarction in patients 
with and without diabetes, undergoing percutaneous coronary intervention. 
Cardiol J 2008;15(5):422-430. 
33.  Karlsberg RP, Cryer PE, Roberts R. Serial plasma catecholamine response early 
in the course of clinical acute myocardial infarction:relation to infarct extent and 
mortality. Am Heart J. 1981 Jul; 102(1):24-9. 
Oman Medical Journal (2011) Vol. 26, No. 2: 85-90